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Background: SULF2 is a 6-O-endosulfatase which removes 6-O sulfate residues from N-glucosamine present on
heparan sulfate (HS). The sulfation pattern of HS influences signaling events mediated by heparan sulfate proteoglycans
(HSPGs) located on cell surface, which are critical for the interactions with growth factors and their receptors. Alterations
in SULF2 expression have been identified in the context of several cancer types but its function in cancer is still unclear
where the precise molecular mechanism involved has not been fully deciphered. To further investigate SULF2 role in
tumorigenesis, we overexpressed such gene in prostate cancer cell lines.
Methods: The normal prostate epithelial cell line RWPE-1 and the prostate cancer cells DU-145, and PC3 were
transfected with SULF2-expressing plasmid pcDNA3.1/Myc-His(−)-Hsulf-2. Transfected cells were then submitted
to viability, migration and colony formation assays.
Results: Transfection of DU-145 and PC3 prostate cancer cells with SULF2 resulted in increased viability, which
did not occur with normal prostate cells. The effect was reverted by the knockdown of SULF2 using specific
siRNAs. Furthermore, forced expression of SULF2 augmented cell migration and colony formation in both
prostate cell lines. Detailed structural analysis of HS from cells overexpressing SULF2 showed a reduction of
the trisulfated disaccharide UA(2S)-GlcNS(6S). There was an increase in epithelial-mesenchymal transition
markers and an increase in WNT signaling pathway.
Conclusions: These results indicate that SULF2 have a pro-tumorigenic effect in DU-145 and PC3 cancer cells,
suggesting an important role of this enzyme in prostatic cancer metastasis.
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Cancer is the second leading cause of death worldwide,
accounting for over 8 million deaths annually. Among
men, prostate, lung and bronchus, and colorectal cancer
accounts for about 50% of all newly diagnosed tumors;
prostate cancer alone accounts for 28% of incidents
among men [1-3]. Its incidence rate is about six times
higher in developed countries when compared to the de-
veloping ones [4,5] being the estimated death count in
the United States 29,720 in 2013 [1].
The current screening method to diagnose prostate can-
cer is based on a measurement of serum prostate specific* Correspondence: ltoma.bioq@gmail.com
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unless otherwise stated.antigen (PSA) levels and a digital rectal examination, while
the decisive diagnosis is based on the results of transrectal,
ultrasound-guided prostate biopsies [6-8]. The current
therapeutic approaches for the advanced stages of prostate
cancer are palliative rather than therapeutic [9]. Thus, de-
termining the molecular pathways that lead to the devel-
opment and progression of the disease is a challenge and
critical for improved therapeutic approaches.
Searching for a better understanding of cancer, as well
as for tumor markers, proteoglycans (PGs) have gained
ground among the molecules involved in tumorigenesis.
PGs are high molecular weight compounds, formed by a
protein skeleton to which glycosaminoglycans (GAGs)
chains are covalently bound [10,11]. They are located pre-
dominantly in the extracellular matrix (ECM) or associ-
ated with cell surface of most eukaryotic cells [12,13].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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late their activity, influencing biological processes such
as embryonic development and cell proliferation [11,13].
Suhovskih et al. [14] reported that in prostate tumors,
complex changes occur in PGs, with decreased expression
of decorin and lumican, an overall increase in syndecan-1
and glypican-1 in tumor stroma, along with the disappear-
ance of agrecan in tumor epithelial cells. All changes re-
sult in the expression patterns of highly individual PGs in
different prostate tumors, which may be potentially useful
as molecular markers for the diagnosis of prostate cancer
and personalized treatment.
HSPGs consist of macromolecules presenting one or
more heparan sulfate (HS) chains covalently bound to
the protein backbone [15-18] and are present on the cell
surface and ECM of all tissues of animals with tissue
organization [19-22]. Among its many roles, membrane
HSPGs can bind to cytokines, chemokines and growth
factors, protecting them from proteolysis. These interac-
tions provide a reservoir of regulatory factors that may be
released by selective degradation of HS chains [15,17,20].
HSPGs can also cooperate with integrins and other cell
adhesion receptors to facilitate cell-ECM adhesion, and
cell motility [16-19]. Finally, they can also act as corecep-
tors for a variety of growth factors, lowering its activation
threshold or changing the duration of the signaling reac-
tions [15-18].
In general, HS chain biosynthesis initiate by alternating
actions of various glycosyltransferases which add residues
of D-glucuronic acid (GlcA) and N-acetyl-D-glucosamine
(GlcNAc). Subsequently, the chain undergoes a series of
polymeric modifications reactions: N-deacetilation/N-
sulfation, the epimerization of the β-Dglucurcnic acid to
α-L-iduronic acid, and O-sulfation at different positions
[23]. Each product is a reaction substrate for the next en-
zyme [22].
Recent studies have shown that after the synthesis, the
HS can also be structurally and functionally modified in
the extracellular compartment where 6-O-endossulfatases
1 and 2 (SULFs) are extracellular enzymes that remove 6-
O-sulfate groups selectively, modulating their biological
activities [24-26]. Recent studies revealed that different
types of tumors present an increase in SULFs expression,
including: hepatocellular carcinoma [27], pancreatic can-
cer [28], squamous cell carcinoma of the head and neck
[29], gastric cancer [30], lung adenocarcinoma and squa-
mous cell carcinoma of the lung [31] for SULF1 and hepa-
tocellular carcinoma [32], lung adenocarcinoma and lung
squamous cell carcinoma [31] for SULF2.
Zhao et al. [33] reported that SULF1 is present in pros-
tatic stromal cells in the transition regions but not in
benign prostatic hyperplasia. Ciampa et al. [34] identi-
fied that SULF2 chromosome locus is associated to pros-
tate cancer susceptibility regions. However, the literatureis ambiguous about the function of SULFs in cancer,
and the enzymes are reported both as anti and as pro-
tumorigenic [25].
Thus, this study aimed to analyze the effects of the
overexpression of SULF2 in prostate cancer cell lines via
analyzing their viability, proliferation, migration and col-
ony formation capabilities. Finally epithelial-mesenchymal
transition markers were also assessed.
Methods
Cell culture
RWPE-1, PC3 and DU-145 cell lines were purchase from
ATCC (American Type Culture Collection, Manassas,
VA, USA). PC3, prostate adenocarcinoma derived from
bone metastatic site, and DU-145, prostate carcinoma de-
rived from brain metastatic site, were grown in Roswell
Park Memorial Institute medium (RPMI, Gibco, Life
Technologies, CA, USA) supplemented with 10% (v/v)
fetal bovine serum (FBS, Cultilab, Campinas, Brazil),
penicillin (100 units/ml) and streptomycin (100 μg/ml,
Invitrogen, Life Technologies, CA, USA) at 37°C in a hu-
midified atmosphere of 5% CO2. RWPE-1, a normal pros-
tate epithelial cell line, was grown in Keratinocyte Serum
Free Medium supplied with bovine pituitary extract and
human recombinant epidermal growth factor (Gibco, Life
Technologies, CA, USA) at 37°C in a humidified atmos-
phere of 5% CO2.
Transfection and expression of SULF2 in culture
Cells were cultured in 24-well plates and transfected
with 5 μg of cDNA coding SULF2, cloned into the vec-
tor pcDNA3.1/Myc-His(−)-HSulf-2 (Addgene plasmid
13004). This plasmid was kindly donated by Prof. Dr.
Steven D. Rosen [19]. For transfection FuGENEHD® re-
agent (Promega Corporation, WI, USA) was used accord-
ing to manufacturer’s instructions. The DNA was diluted
in OptiMEM (Invitrogen, Life Technologies Corporation,
CA, USA) combined with FuGENE and incubated for
20 min at room temperature. After incubation, the com-
plex was added to the respective culture medium of each
cell line. The cells were cultured for 20 days in the pres-
ence of geneticin (Promega Corporation, WI, USA) and
clonally selected in accordance to the level of SULF2
overexpression.
Knockdown of SULF2 using siRNA
SULF2 gene silencing was performed with siRNA preset
by the manufacturer (Life Technologies Corporation,
CA, USA). Three siRNAs were used for the gene, in
addition to the positive (GAPDH) and negative (scram-
ble sequence) controls: human SULF2 siRNA1 F: GGAC
AACACGUACAUCGUAtt and R: UACGAUGUACGU
GUUGUCCag; human SULF2 siRNA2 F: GGUGCUAC
AUCCUAGAGAAtt and R: UUCUCUAGGAUGUAGC
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UCGGGAAtt and R: UUCCCGAAGAAAGCUGUCCgg.
Cells were plated in 24-well plates so that they were 60-
80% confluent by the time of transfection, according to
the manufacturer’s instructions. On the test day, the
siRNA was added to the Lipofectamine RNAiMAX (Life
Technologies Corporation, CA, USA) and incubated for
20 min. Finally, the solution was added to the cell media
without FBS and no antibiotics. After 8 hours of incuba-
tion, the medium was replaced by the respective culture
medium of each cell line. Viability assays and cell migra-
tion were performed at different times to analyze the
consequences of silencing SULF2.
Real-time PCR
The expression of SULF2 was analyzed before and after
the transfection of cell lines. Total RNA was extracted
from cell lines (2.106 cells) using Trizol® reagent (Invitrogen,
Life Technologies Corporation, CA, USA). The primers
used for the amplification reaction were designed from the
research database sequences and data already published:
human SULF2 F: CTGTGGGAAGGCTGGGAAGG and
R: TGAGAGTGCGTGCTTGCTTTC; human beta-actin
F: ACCAACTGGGACGACATGGAGAAA and R: TAGC
ACAGCCTGGATAGCAACGTA; human GAPDH F: TC
GACAGTCAGCCGCATCTTCTTT and R: ACCAAATCC
GTTGACTCCGACCTT. The Real-Time PCR reaction
was performed using SYBR®-Green PCR Master Mix, in-
cluding AmpliTaq-GOLD polymerase (Applied Biosystems,
USA) on ABI PRISM 7500 Real Time PCR System
(Applied Biosystems, USA). All reactions were performed
in triplicate.
Western blotting
To verify the overexpression of SULF2, cellular proteins
were extracted from both the cell extract and the culture
medium. The adherent cells were removed from Petri
dishes using cell lysis buffer (Cell Signaling, MA, USA)
containing protease inhibitor cocktail (Roche, Mannheim,
Germany) and then exposed to sonication. The collected
conditioned medium was concentrated on Centricon cen-
trifugal filter units (Millipore, Merck, MA, USA). 100 μg
of samples resuspended in non-reducing sample buffer
(Tris–HCl 100 mM pH 6.8, 4% SDS, 0.02% Blue bromo-
phenol, 20% glycerol) were applied to 7.5% polyacrylamide
gel and subjected to SDS-PAGE (80 V for 2 h). After elec-
trophoresis, the proteins were transferred from the gel to
a nitrocellulose membrane, incubated overnight at 4°C
with primary anti-human SULF2 produced in rabbit
(H-80, Santa Cruz Biotechnology, CA, USA) and human
anti-beta-actin produced in goat (1:500–1000) (Santa Cruz
Biotechnology, CA, USA) diluted in TBS with 1% BSA, and
then incubated with IgG secondary antibody conjugated
with peroxidase (1:2000). The membrane was incubatedwith the SuperSignal West Pico chemiluminescent sub-
strate (Thermo Fischer Scientific, IL, USA). The chemilu-
minescent signal was detected using the gel documentation
system G:BoxChemi HR16573 (Syngene, Frederick, MD,
USA). Densitometric analysis of bands was performed using
ImageJ (http://rsb.info.nih.gov/ij/) software, using beta-actin
as a control for each sample.
Incorporation of sodium [35S]-sulfate for Structural
Analysis of Glycosaminoglycans (GAGs)
Cells transfected or not with pcDNA3.1/Myc-His-(−)-HSulf-
2 were subjected to metabolic labeling with [35S]-sulfate in
a final concentration of 100 μCi/ml. After 24 h, the
medium was collected, the cells were removed from the
plate with 1 mL of 0.025% EDTA and lysed with 1 ml of
3.5 M urea in Tris–HCl 10 mM, pH 8.0. The extracellular
matrix was removed with 5% trypsin, 4% EDTA. Cell ex-
tract, medium and extracellular matrix were subjected to
proteolysis with maxatase (4 mg/ml in 50 mM Tris–HCl,
pH 8.0 containing 1.5 mM NaCl) at 60°C for 24 h. After
proteolysis, GAGs were precipitated with 3 volumes
of ethanol at −20°C for 24 h. GAGs were analyzed by
electrophoresis in agarose gel in PDA buffer (0.05 M
1,3-diaminepropane-acetate) [35]. GAGs were precipi-
tated by 0.2% cetyltrimethylammonium bromide (Merck,
Darmstadt, Germany) for 1 h. The gels were exposed
to a radiosensitive film Multipurpose (Packard Instruments
Co.) for 24 h, identified in Cyclone® system (Storage
Phosphor system- Packard Instr) and quantified using the
Opti Quanti® software. GAGs extracted from each cell
type were submitted to enzymatic degradation with hepar-
itinases I and II from Flavobacterium heparinum for HS
disaccharide analyses [36]. The degradation products were
then analyzed in a PhenoSphere™ SAX 80 Å LC HPLC
Column 150 × 4.6 mm. The Δ-disaccharides were eluted
in a linear gradient of 0–1 M NaCl for 30 min at a flow
rate of 1 ml/min. Individual fractions (0.5 ml) were col-
lected and counted on a Micro-Beta counter. HS disaccha-
rides were generated for three independent experiments
and the products of digestion combined prior to analysis
to allow detection. Hence, the results represent an overall
trend but, cannot be further analyzed statistically.
Immunofluorescence
Transfected cells were seeded on coverslips at a concen-
tration of 105 cells/ml. After 3 days, cells were fixed in
methanol:acetone (1:1) for 2 min and incubated with primary
antibody anti-SULF2 (H-80, Santa Cruz Biotechnology,
CA, USA), polyclonal anti-human vimentin produced in
goat (Santa Cruz Biotechnology, CA, USA), monoclonal
anti-human-β-catenin produced in mouse (MAB13291-
100, R&D Systems, MA, USA); Alexa 594 conjugated
phalloidin (Invitrogen, Life Technologies Corporation, CA,
USA) in PBS containing 5% FBS for 1 h. Subsequently,
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with a fluorescent marker diluted 1:200 in PBS for 40 min
in the dark. Cell nuclei were stained with DAPI 1:1000 in
PBS with 0.01% saponin for 30 min. The controls were
performed by omitting the primary antibody. The staining
was observed and analyzed with a fluorescence micro-
scope Nikon E-600 confocal microscope and LSM - 510
NLO (Zeiss, Germany).
Flow cytometry
106 cells were fixed with 2% paraformaldehyde in PBS
for 30 min. Staining was performed by incubating cells
with primary antibodies: monoclonal antibody anti-human
CD44 produced in mouse (Santa Cruz Biotechnology, CA,
USA); polyclonal anti-human vimentin produced in goat
(Santa Cruz Biotechnology, CA, USA); monoclonal anti-
human N-cadherin produced in rabbit (Cell Signaling,
MA, USA); monoclonal anti-human WNT 3A produced
in rat (MAB1324-050, R&D Systems, MA, USA), monoclo-
nal anti-human-β-catenin produced in mouse (MAB13291-
100, R&D Systems, MA, USA); for 2 h, followed by
incubation with anti-IgG conjugated to Alexa 488 or 637
(1:300 dilution, Invitrogen, Life Technologies Corporation,
CA, USA) for 40 min. Data were collected using the
FACSCalibur flow cytometer (Becton Dickinson, CA,
USA).
Viability assay
For the colorimetric proliferation assay, 104 cells/well
were cultured in 96-well plates. After different times,
cells were incubated with 20% of the dye bromide [3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide] (MTT, 5 mg/ml) (Sigma Chemical Co., MO, USA).
For 2 hours at 37°C. The medium was carefully removed
and formazan crystals produced were solubilized by
addition of DMSO (MP Biomedicals, OH, USA). The plates
were shaken for 10 min and the absorbance was measured
in EXL800 ELISA plate reader, Universal MICROPLAT
Reader (Bio-TEK Instruments, Inc.) at 540 nm. Cell viabil-
ity was estimated by comparing the absorbance values
with the controls at different times with the absorbance
values of the controls.
Wound healing assay
2.105 cells/well were seeded in 24-well plates. After reach-
ing confluence, a scratch was performed using a 200 μl
pipette tip in the center of the plate. Closure of the wound
was monitored using an inverted optical microscope
(Zeiss, Germany) and images obtained by camera (Sony
Cyber-shot) attached to the microscope.
Cell invasion assay
2.105 cells were seeded in Millicell® chambers (Millipore,
MA, USA) containing polycarbonate membranes withpore diameter of 8 μm in medium without FBS. These
chambers were placed in 24-well plates containing media
with 10% FBS in the lower chamber. After 24 hours at
37°C and 5% CO2, the membranes were washed thor-
oughly with 10 mM PBS, fixed for 30 min in 4% parafor-
maldehyde, and stained with 0.2% crystal violet for 10 min.
The remaining cells on the upper chamber were removed
with a cotton swab. The cells were observed using an
inverted optical microscope with photographic images
obtained by camera (Sony Cyber-shot) attached to the
microscope. To quantify cell migration, stained cells were
solubilized in 10% acetic acid and absorbance was de-
tected at 560 nm.
Colony formation assay (soft agar)
24-well plates were coated with 300 μl of 0.7% agarose
and maintained at 4°C for 30 min. 6.103 cells were resus-
pended in medium containing 0.35% agarose and plated
on plates previously covered with agarose. Cells were
kept at 37° C with 5% CO2 for 1 h, when it was added
the respective culture medium of each cell. Formation of
colonies was followed for 20 days. The colonies were
counted and measured using an inverted optical micro-
scope (Zeiss, Germany).
Co-cultures of prostate cancer and fibroblasts
Sterile glass cloning rings (O-rings) were placed on top
of glass coverslips in 24-well culture dishes. Human fi-
broblasts isolated from amniotic fluid were kindly do-
nated by Dr. Walter Pinto Júnior. Fibroblasts were
seeded around the O-ring at a density of 1.5.104 cells
per well in DMEM containing 10% FBS. Prostate cancer
cells were seeded inside the O-ring at a cell density of
0.5x104 cells per well in RPMI containing 10% FBS. The
cells were maintained in culture for 48 h (37°C, 5%
CO2). The O-rings were then removed, and the cells
were maintained in culture until the cells spread out into
the O-ring area (2 days). The cells were sequentially
fixed using 4% paraformaldehyde and submitted to im-
munofluorescence, as previously described.
Statistical analyses
Statistical analyzes were performed using Student’s T test
in Microsoft Excel software (Microsoft, WA, USA). The
results were presented as the mean ± standard deviation
of triplicates of each experiment and were considered
statistically significant if p ≤ 0.05. All experiments were
performed three times, unless stated otherwise.
Results
SULF2 expression in normal and prostate cancer cells
SULF2 gene expression was analyzed in RWPE-1 normal
prostate epithelial cells and in LNCap, PC3 and DU-145
prostate cancer cells. Total RNA was extracted from the
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electrophoresis after PCR. Our result showed that SULF2
is similarly expressed in normal and prostate cancer cells
(Figure 1A). Subsequently, we transfected RWPE-1 nor-
mal cell, PC-3 and DU-145 cancer cells with the expres-
sion plasmid pcDNA 3.1 containing the SULF 2 gene. AsFigure 1 SULF2 expression in prostate cancer cells. Normal prostate ep
DU-145 SULF2 mRNA level was analyzed by RT-PCR in agarose gel (A). RWP
plasmid pcDNA3.1/Myc-His(−)Hsulf-2 (Addgene plasmid 13004) or empty vec
not transfected. SULF2 mRNA expression was confirmed with quantitat
GAPDH expression (B). The overexpression of SULF2 was also confirmed by
immunofluorescence analyzed in confocal microscope (D). The data fro
as the average ± standard deviation. (CTRL: not transfected cells; VECTO
with SULF2 containing vector). Scale bars 20 μm. *P ≤ 0.05.control, we transfected the same cells with the empty vec-
tor. The cells were clonally selected and the transfection
efficiency confirmed by quantitative RT-PCR, western
blotting and immunofluorescence. We observed a signifi-
cant increase (50-fold) of SULF2 gene expression in the
transfected cells (Figure 1B). The overexpression of SULF2ithelial cell line RWPE-1, and prostate cancer cell lines LNCap, PC3 and
E-1, PC3 and DU-145 cells were transfected with either SULF2 expressing
tor using Fugene reagent (Promega). The control cells (CTRL) were
ive real-time PCR. The expression level of each gene was normalized by
protein western blotting under non-reducing conditions (C) and
m each experiment was obtained in triplicate and are represented
R: cells transfected with the empty vector; SULF2: cells transfected
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fected cells (data not shown). Moreover, western blotting
analyzes demonstrated that SULF2 was increased in cells
extracts, but mainly in the medium (Figure 1C). The in-
creased expression of SULF2 was also observed by im-
munofluorescence (Figure 1D).
SULF2 enzymatic activity in prostate cancer cells
In order to analyze whether the forced overexpression of
SULF2 gene resulted in up-regulation of the active enzyme,
we verified the content of sulfated HS in PC3 and DU-
145 transfected cells. Indeed, we observed a decrease of
approximately 50% of sulfated HS in all of the compart-
ments studied, medium, cell, and ECM, in both cells
(Figure 2A). We also performed the analyses of HS di-
saccharides from PC3 and DU-145 transfected cells,
using a strong anion-exchange (SAX) column. It was
possible to observe an expressive decrease of the trisul-
fated disaccharide UA(2S)-GlcNS(6S) (Figure 2B). Our
result is consistent with previous data from the litera-
ture, which describes that the trisulfated disaccharide
from HS is the main substrate for both SULF1 and
SULF2 [24,26,37,38].
Consequences of SULF2 overexpression in cell viability
and migration
After analyzing the effects of SULF2 forced expression
on the structure of HS from prostate cancer cells, we
studied the differences on cell viability and migration.
Initially, cell viability was measured by MTT colorimet-
ric assay. The overexpression of SULF2 had no effect on
the viability of RWPE-1 cells (Figure 3A). However, both
prostate cancer cells, PC3 and DU-145 presented in-
crease on cell viability. The migration was also analyzed
by wound healing assay. A scratch was performed on
confluent cell cultures and the cells were allowed to mi-
grate for 24 h. Interestingly, the normal prostate epithe-
lial cell line RWPE-1 transfected with SULF2, did not
present any increase on cell migration (Figure 3B). How-
ever, prostate cancer cells showed a robust migratory
phenotype. These results indicate that forced expression
of SULF2 increased cell viability and migration solely on
prostate cancer cells, but did not enhance these charac-
teristics on normal cells.
Effects of SULF2 knockdown on prostate cells
In order to confirm that the previous cell behaviors were
indeed acquired due to the overexpression of SULF2, we
studied the consequences of SULF2 knockdown on the
same prostate cells. For this purpose, prostate cells were
transfected with siRNAs targeting SULF2 mRNA. Gene
silencing was confirmed by quantitative RT-PCR
(Figure 4A), and the levels of SULF2 mRNA were reduced
in at least 95%. After that, the cells were submitted toviability and migration assays as previously described.
Interestingly, the knockdown of SULF2 reduced the cell
viability of RWPE-1 normal prostate cells, as well as re-
duced the cell viability of DU-145 and PC3 prostate can-
cer cells (Figure 4B). In addition, SULF2 silencing
impaired cell migration (Figure 4C). Apparently, the
overexpression of SULF2 was not sufficient to increase
normal epithelial prostate cells growth and migration.
However, the enzyme must be important for these cell
properties, since its knockdown also decreased normal
prostate cells migration and viability.SULF2 overexpression increases colony formation and
invasion of prostate cancer cells
In order to determine whether SULF2 increase was able
to exacerbate the tumorigenic phenotype of prostate
cancer cells in vitro, PC3 and DU-145 cells were submit-
ted to colony formation and transmigration assays. For
transmigration assay, cancer cells were plated on the top
of membranes with pore diameter of 8 μm and allowed
to migrate for 24 h. DU-145 cancer cells transfected with
SULF2 presented a 3-fold increase on migration through
the membrane, and PC3 cancer cells transfected with
SULF2 presented a 2-fold increase on migration
(Figure 5A). For colony formation assay, the cancer cells
were embedded in soft agar and the colonies growth was
followed for 20 days. DU-145 and PC3 prostate cancer
cells overexpressing SULF2 presented an increase of 3-
fold on the size of the colonies formed, compared to
cells transfected with empty vector (Figure 5B). Equally
important, the SULF2 overexpressing cells also formed
more colonies on soft agar (Figure 5B).SULF2 overexpression increases the expression of
epithelial-mesenchymal transition markers
The epithelial-mesenchymal transition (EMT) is a key
developmental program that is often activated during
cancer invasion and metastasis [39]. Recently, EMT
markers have been found to confer malignant traits,
such as motility, invasiveness and resistance to apoptosis
[39]. Since we have observed an increase of these char-
acteristics on prostate cancer cells with forced expres-
sion of SULF2, we decided to analyze some EMT
markers in these cells. Thus, prostate cancer cells were
immunostained for CD44, vimentin, and N-cadherin and
the presence as well as their quantity analyzed by flow
cytometry. Indeed, PC3 and DU-145 prostate cancer
cells overexpressing SULF2 exhibited increased levels of
CD44, vimentin, and N-cadherin (Figure 6). Hence, our
results indicate that prostate cancer cells overexpressing
SULF2 become more undifferentiated, which is in agree-
ment with the increased cell growth and migration pre-
sented by them.
Figure 2 SULF2 enzymatic activity in prostate cancer cells. GAGs labeled with [35S]Na2SO4. were purified from the culture medium (MEDIUM),
the cancer cells (CELL) extracted with EDTA, and the matrix (MATRIX) produced by cells. The content of GAGs from these compartments was
analyzed through agarose gel electrophoresis. The gel was exposed to a radiosensitive screen and quantification was performed by densitometry
with Opti-Quanti Software (A). Each sample was digested using a mixture of heparin lyases and analyzed on a PhenoSphere™ 5 μm SAX 80 Å LC
Column 150 × 4.6 mm. Δ-disaccharide were eluted with a linear gradient of NaCl 0–1 M over a 30-min period at a flow rate of 1 ml.min-1.
Individual fractions (0.5 ml) were collected and counted using a micro-beta counter (B). The bars indicate the average of three independent
experiments. The arrows show the trisulfated disaccharide UA(2S)-GlcNS(6S). *P≤ 0.05.
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signaling pathway [25,37]. Therefore, we analyzed the pres-
ence of WNT 3A and β-catenin in DU-145 and PC3 cells
overexpressing SULF2. By flow cytomery, we observed anincrease of active unphosphorylated β-catenin in both
SULF2 transfected cells (Figure 7A). Moreover, the pro-
portion of cells presenting both WNT 3A and β-catenin
(Figure 7B) also increased. DU-145 cancer cells overexpressing
Figure 3 Forced expression of SULF2 increased prostate cancer cells viability and migration. For MTT assays, cells were plated into 96-well
plates at 3000 cells per well and incubated in 10% FBS for 24 and 48 hours, lysed in DMSO and absorbance was measured in 540 nm (A). Scratch
wounds were made in confluent cell culture monolayers with a 200-μL pipette tip; photomicrographs of the wounds were taken at 0 and
24 hours thereafter (B). (VECTOR: cells transfected with the empty vector; SULF2: cells transfected with SULF2). *P≤ 0.05.
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3A and β-catenin respectively, in comparison to 20.7%
in control cells transfected with empty vector. PC3 cells
overexpressing SULF2 showed 40.2% of cells double
stained for WNT 3A and β-catenin respectively, com-
pared to 26.0% in control cells transfected with empty
vector. Finally, by confocal microscopy, we could de-
tect β-catenin located close to the cells membrane in
control cells, while cells with forced expression of
SULF2, presented a nuclear staining for β-catenin (ar-
rows, Figure 7C).Effects of SULF2 overexpression in stroma-cancer
co-cultures
The O-ring co-culture system is an attempt to mimic a
tumor microenvironment. The stromal cells are seeded
and cultured immediately around the tumor cell line,
allowing cell–cell contact besides establishing a gradient
of soluble factors throughout the stromal cells, similar to
that found in tissues [35]. As expected, after 2 days of
culture, PC3 and DU-145 prostate cancer cells overex-
pressing SULF2 had already connected to fibroblasts,
whereas the control cells transfected with empty vectors
Figure 4 Knockdown of SULF2 decreased viability and migration of prostate cells. RWPE-1 epithelial prostate cells and DU-145 and PC3
prostate cancer cells were transfected with siRNA (Life Technologies) targeting SULF2. To silence SULF2 gene, trials with siRNA preset by the
manufacturer (Life Technologies, CA, USA) were performed as described in Methods. Three shRNAs were used to each gene, in addition to the
positive (GAPDH) and negative (scramble sequence) controls. The gene silencing was confirmed by Real Time PCR 48 h after transfection (A).
MTT viability assay (B) and wound healing assay (C) were performed as described previously. (CTRL NEG: scramble siRNA sequence). *P≤ 0.05.
Vicente et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:25 Page 9 of 16
Figure 5 SULF2 overexpression increased prostate cancer cells invasiveness and colony formation. For transwell migration assay, cells
were plated on the top chamber of transwell membranes (8 μm pore size). Migrating cells were fixed with 4% formaldehyde and stained with
crystal violet (A). The graphics represent the relative migration (B). For colony formation assay cells were diluted in medium containing 0.35%
agar and colonies were photographed after 20 days (C). Tables indicate the number and the size of colonies formed by prostate cancer cells (D).
(VECTOR: cells transfected with the empty vector; SULF2: cells transfected with sulfatase 2 containing vector). *P≤ 0.05.
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ably occurred due to the increased migration presented
by PC3 and DU-145 with forced expression of SULF2.
Moreover, by using this system coupled to immunocyto-
chemistry, we analyze the region of intersection between
stromal cells and tumor cells (Figure 8). We observed an
apparent increase in vimentin in the intersection areabetween cancer cells and fibroblasts for both transfected
cells.
Discussion
Recent progress in cancer biology suggests that a limited
number of pathways are critical for initiating and main-
taining deregulated cell proliferation, and migration,
Figure 6 Forced expression of SULF2 on prostate cancer cells increased EMT markers. DU-145 (A) and PC3 (B) prostate cancer cell lines
overexpressing SULF2 were stained with anti-CD44, anti-vimentin and anti-N-caderin antibodies and analyzed by flow cytometry, as described in
methods. The graphics represent relative quantity of positively stained cells (C, D). *P≤ 0.05.
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cer advance and metastasis [32]. New agents in develop-
ment, target several of these critical pathways and many
of them have ligands to which cell-surface or ECM PGs
act as co-receptors [16]. Studies of the newly discovered
family of HS 6-O-endosulfatases, SULF1 and SULF2, sug-
gest that HSPGs in the ECM or on the cell surface can
sequester growth factor ligands and cytokines in a sulfation-
dependent manner and release them when desulfated by
heparan-degrading endosulfatases [25].
The SULFs are a family of enzymes that are secreted via
the Golgi and are located on the cell surface or released
into the ECM. These enzymes selectively remove the 6-O-
sulfate groups from HS, with preference for those present
in trisulfated disaccharides [24,25]. Importantly, such par-
tial and oriented desulfatation can differentially modify
the interaction of protein ligands to HS. When SULFs re-
move the 6-sulfate, they trigger the release of HSPGs li-
gands, allowing them to act in cells.
A limited number of studies reported the involvement
of SULFs in prostate cancer. SULF1 is present in prostatic
stromal cells in the transition regions between cancer and
stroma and SULF2 chromosome locus is associated to
prostate cancer susceptibility regions [33,34].
In the present study, we found that SULF2 acts as an
oncogenic protein in prostate cancer cells once cells over-
expressing SULF2 presented increased cell viability andmigration, which has already been observed in different
tumor cells previous studied, where the overexpression of
SULF2 had also been performed [25,31,32]. These effects
were reverted when SULF2 mRNA was silenced using siR-
NAs. Interestingly, SULF2 knockdown on normal prostate
epithelial cells, RWPE-1, has also decreased cell growth
and migration.
Moreover, DU-145 and PC3 prostate cancer cells with
forced expression of SULF2 presented an augmentation
of invasiveness and tumor colony formation in vitro.
Therefore, SULF2 appears to act as a proto-oncogene
in prostate cancer cells, increasing their ability to growth
and migrate. However as cancer is a multifactorial dis-
ease, the augmentation of SULF2 alone was not suffi-
cient to produce these effects in normal prostate
epithelial cells.
In order to determine the mechanisms involved in the
increase of cell growth and migration, we investigated
the effects of SULF2 overexpression on EMT markers.
In recent years, EMT has been found to confer malig-
nant characteristics to cells, such as motility, invasive-
ness, and resistance to apoptosis, on neoplastic cells
[40-42]. During the process of tumor metastasis, which
is often enabled by EMTs [43], disseminated cancer cells
would seem to require self-renewal capability, similar to
that exhibited by stem cells, in order to establish new
focus of metastases. This raises the possibility that the
Figure 7 WNT signaling pathway in SULF2 ovexpressing prostate cancer cells. DU-145 and PC3 cells were immunostained with WNT 3A
and β-catenin antibodies (R&D) and analyzed by flow cytometry, as described in methods. The graphics represent relative quantity of positive cells
(A). Representative pictures are shown, indicating the percent of double-stained cells (B). Prostate cancer cells were immunostained for β-catenin
and analyzed by confocal microscopy. The nuclei (blue) were stained with DAPI. (C). (VECTOR: cells transfected with empty vector, SULF2: cells
transfected with SULF2 expressing plasmid). *P≤ 0.05.
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may also provide self-renewal capability to the dissemin-
ating cancer cells.
We found that the up-regulated SULF2 cells increased
EMT markers, including CD44, vimentin and N-cadherin.
CD44 is a multifunctional class I transmembrane glyco-
protein [44,45] that generally acts as a specific receptorfor hyaluronic acid, promoting migration in normal cells.
Also, CD44 presents cytokines and chemokines to their
complimentary receptors on the cellular membrane [41].
It is mainly associated with proteins that monitor the
extracellular changes and is critical in regulating cell adhe-
sion, proliferation, growth, survival, motility, migration,
angiogenesis, and differentiation [39], and is highly
Figure 8 Cocultures of prostate cancer cells overexpressing SULF2 and stromal cells. Prostate cancer cells (PC3 or DU-145) were seeded
inside the O-ring and fibroblasts stromal cells were seeded around the O-ring. The O-ring was removed and the cultures maintained in the same
conditions until the cells filled the O-ring area. The cells were firstly visualized in phase contrast in optical microscope in bright field. Immunolocalization
of actin, SULF2, vimentin, and fibronectin were performed after fixation of the cells with 2% formaldehyde. The nuclei (blue) were stained with DAPI. F:
fibroblasts, P: prostate cancer cells. Scale bar represents 100 μm.
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variant form [45,46].
Loss of E-cadherin expression in cancer cells may be as-
sociated with gain of N-cadherin expression, leading to a
fibroblastic phenotype with increased motility and invasive
potential in vitro and in vivo [47-49]. Moreover, the re-
duced expression of E-cadherin, abnormal expression of
N-cadherin, transformation from E-cadherin to N-cadherin
and the increased expression of TGF-β 1 and Twist play
an important role in the occurrence and development of
prostate cancer [50,51].
Vimentin is an intermediate filament which supports
cellular mechanostructural integrity participating in cell
adhesion, migration, survival, and signaling [52,53]. High
vimentin expression has been reported in bone metastasis
of prostate cancer and has been implicated in prostate
cancer cell invasion [54,55]. Consistent with this result, we
observed an up-regulation of vimentin expression in co-
cultures of stromal cells and metastatic prostate cancer
cells. Accordingly, our previous work had already demon-
strated an increased expression of vimentin when stromal
cells were exposed to prostate tumor cell lines, besides
changes in its cellular arrangement from punctate to
a fibrilar distribution [53].
A series of studies have demonstrated that the WNT/
β-catenin signaling pathway is one of the major path-
ways involved in EMT regulation in different types of
tumor, including prostate cancer [56-59]. Interestingly,
one of the known consequences of SULF overexpression
is the promotion of WNT signaling pathway. According
to the model proposed by Ai et al. [32], the action of
SULFs weakens the association of WNT to HSPGs at
the cell surface, which allows the WNT to activate its
Frizzled signal transducing receptors. β-catenin is stabi-
lized by WNT and translocated into the nucleus, where it
binds to the T cell factor and lymphoid enhancer factor
(TCF/LEF) family of transcriptional cofactors. Succes-
sively, β-catenin–TCF/LEF complexes activate transcrip-
tional cascades that induce EMT programs.
Our previous study, with human colorectal cancer cell
lines, confirmed that the forced expression of SULFs re-
sults in increased WNT 3A signaling pathway, evinced by
the accumulation of active unphosphorylated β-catenin
[60]. Consistent with this, prostate cancer cells overex-
pressing SULF2 presented an increase of WNT 3A and
β-catenin double-stained cells, in addition to a nuclear lo-
cation of β-catenin. Therefore, our results indicate that
the WNT/β-catenin signaling pathway could be regulating
the EMT in those cells.
In summary, SULF2 overexpression increases metastatic
prostate cancer cells growth and migration, leading to an
augmentation of tumor colony formation and invasive-
ness. In addition, forced expression of SULF2 resulted in
an increment of EMT markers and in a stronger contactbetween prostate cancer cells and stromal cells. Therefore,
SULF2 may contribute to the metastatic process in pros-
tate cancer.
Conclusions
Our results demonstrated a possible pro-tumorigenic role
of SULF2 in prostate cancer. However, due to the limita-
tions of in vitro experiments, further in vivo studies are
necessary to better understand the complex function of
SULF2 in prostate cancer. As previous studies have
already indicated an involvement of SULFs in different
types of tumors [22-27], and as there are some evidences
of the involvement of SULFs in prostate cancer [28,29],
we believe that the study of this enzyme will contribute to
a better understanding of this disease, as well as emerge
with new therapeutic opportunities.
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